Literature DB >> 26201264

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.

Oscar B Lahoud1, Craig S Sauter, Paul A Hamlin, Parastoo Bahrami Dahi.   

Abstract

High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HDT/ASCT) can improve survival in patients with lymphoma. Limited experience is available on the safety and efficacy of HDT/ASCT in elderly patients. In this article, we review the published data on the role of HDT/ASCT in management of lymphoma in older patients. Based on available data, evaluation of comorbidities, functional status, and comprehensive geriatric assessment (CGA) will help identify those who can benefit most from this intervention. Prospective clinical trials focusing on HDT/ASCT in older patients with lymphoma are needed to establish optimal management protocols in this select population.

Entities:  

Mesh：

Year:  2015        PMID： 26201264      PMCID： PMC5542393          DOI： 10.1007/s11912-015-0465-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  99 in total

1.  Autologous and isologous bone marrow storage and infusion in the treatment of myelo-suppresson.

Authors:  N B KURNICK
Journal:  Transfusion       Date:  1962 May-Jun       Impact factor: 3.157

2.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation.

Authors:  Carolien M Woolthuis; Niccoló Mariani; Rikst Nynke Verkaik-Schakel; Annet Z Brouwers-Vos; Jan Jacob Schuringa; Edo Vellenga; Joost T M de Wolf; Gerwin Huls
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

4.  Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.

Authors:  A Olivieri; D Capelli; M Montanari; M Brunori; D Massidda; A Poloni; M Lucesole; R Centurioni; M Candela; M C Masia; C Tonnini; P Leoni
Journal:  Bone Marrow Transplant       Date:  2001-06       Impact factor: 5.483

5.  Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

Authors:  Ann S LaCasce; Jonathan L Vandergrift; Maria A Rodriguez; Gregory A Abel; Allison L Crosby; Myron S Czuczman; Auayporn P Nademanee; Douglas W Blayney; Leo I Gordon; Michael Millenson; Ann Vanderplas; Eva M Lepisto; Andrew D Zelenetz; Joyce Niland; Jonathan W Friedberg
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

6.  High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

Authors:  Ajay K Gopal; Joseph G Rajendran; Ted A Gooley; John M Pagel; Darrell R Fisher; Stephen H Petersdorf; David G Maloney; Janet F Eary; Frederick R Appelbaum; Oliver W Press
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

7.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.

Authors:  Philip L McCarthy; Theresa Hahn; Anna Hassebroek; Christopher Bredeson; James Gajewski; Gregory Hale; Luis Isola; Hillard M Lazarus; Stephanie J Lee; Charles F Lemaistre; Fausto Loberiza; Richard T Maziarz; J Douglas Rizzo; Steven Joffe; Susan Parsons; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-06       Impact factor: 5.742

10.  Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.

Authors:  Luís Villela; Anna Sureda; Carme Canals; Miguel Angel Sanz; Rodrigo Martino; David Valcárcel; Albert Altés; Javier Briones; Marta Gómez; Salut Brunet; Jorge Sierra
Journal:  Haematologica       Date:  2003-03       Impact factor: 9.941
View more
  1 in total

1.  A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

Authors:  R Parody; I Sánchez-Ortega; A Mussetti; B Patiño; M Arnan; H Pomares; E González-Barca; S Mercadal; C Boqué; C Maluquer; I Carro; M Peña; V Clapés; S Verdesoto; G Bustamante; A C Oliveira; C Baca; E Cabezudo; C Talarn; L Escoda; S Ortega; N García; M Isabel González-Medina; Mar Sánchez-Salmerón; C Fusté; J Villa; E Carreras; E Domingo-Domènech; A Sureda
Journal:  Bone Marrow Transplant       Date:  2021-10-28       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.